A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors

Annals of Oncology

Volumn 16, Issue 6, 2005, Pages 958-965

  Desai, A A ^a,b   Schilsky, R L ^a   Young, A ^c   Janisch, L ^a   Stadler, W M ^a   Vogelzang, N J ^a   Cadden, S ^c   Wright, J A ^c   Ratain, M J ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Department of Medicine   (United States)

^c Lorus Therapeutics Inc   (Canada)

Author keywords

Antisense therapies; GTI 2040; Pharmacokinetics; Phase I trial; Phosphorothioate oligonucleotides; Ribonucleotide reductase inhibition

Indexed keywords

AMINOTRANSFERASE; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTISENSE OLIGONUCLEOTIDE; GTI 2040; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RIBONUCLEOTIDE REDUCTASE; STEROID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE INFECTION; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; INTESTINE OBSTRUCTION; LIVER TOXICITY; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 21344458583     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi178     Document Type: Article

References (26)

1. Gewirtz AM. Oligonucleotide therapeutics: a step forward. J Clin Oncol 2000; 18: 1809-1811.
2. Buolamwini JK. Novel anticancer drug discovery. Curr Opin Chem Biol 1999; 3: 500-509.
3. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: state of the art and future prospects. Blood 1998; 92: 712-736.
4. Ho PT, Parkinson DR. Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol 1997; 24: 187-202.
5. Galderisi U, Cascino A, Giordano A. Antisense oligonucleotides as therapeutic agents. J Cell Physiol 1999; 181: 251-257.
6. Kuss B, Cotter F. Antisense-time to shoot the messenger. Ann Oncol 1999; 10: 495-503.
7. Cory J. Purine and Pyrimidine Nucleotide Metabolism. Textbook of Biochemistry with Clinical Correlations, 4th edition. New York, USA: Wiley-Liss 1997; 489-523.
8. Zhou B, Yen Y. Characterization of the human ribonucleotide reductase M2 subunit gene; genomic structure and promoter analyses. Cytogenet Cell Genet 2001; 95: 52-59.
9. Thelander L, Berg P. Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase. Mol Cell Biol 1986; 6: 3433-3442.
10. Investigators Brochure Lorus Therapeutics; Toronto, Canada.
11. Engstrom PF, MacIntyre JM, Mittelman A et al. Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278). Am J Clin Oncol 1984; 7: 313-318.
12. Goan YG, Zhou B, Hu E et al. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 1999; 59: 4204-4207.
13. Puckett WHP, Xu YZ. Gemcitabine: metabolism mechanisms of actionand self-potentiation. Semin Oncol 1995; 22: 3-10.
14. Fan H, Villegas C, Huang A et al. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res 1998; 58: 1650-1653.
15. Fan H, Villegas C, Huang A et al. Suppression of malignancy by the 3′ untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs. Cancer Res 1996; 56: 4366-4369.
16. Lee Y, Vassilakos A, Feng N et al. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 2003; 63: 2802-2811.
17. Cunningham CC, Holmlund JT, Geary RS et al. A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 2001; 92: 1265-1271.
18. Morris MJ, Tong WP, Cordon-Cardo C et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002; 8: 679-683.
19. Rudin CM, Holmlund J, Fleming GF et al. Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res 2001; 7: 1214-1220.
20. Waters JS, Webb A, Cunningham D et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812-1823.
21. Marcucci G, Byrd JC, Dai G et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003; 101: 425-432.
22. Galbraith WM, Hobson WC, Giclas PC et al. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 1994; 4: 201-206.
23. Henry SP, Giclas PC, Leeds J et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 1997; 281: 810-816.
24. Henry SP, Novotny W, Leeds J et al. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev 1997; 7: 503-510.
25. Rini BI, Vogelzang NJ, Dumas MC et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000; 18: 2419-2426.
26. Mani S, Vogelzang NJ, Bertucci D et al. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer 2001; 92: 1567-1576.